Irish pharmaceutical cannabis manufacturer Dunbar Pharmaceuticals has today launched the first plant-derived dronabinol active ingredient into the UK market.
Welcome to Business of Cannabis’ new weekly strategic digest tracking the financial health, market moves, and corporate developments shaping the European cannabis sector.
Argent BioPharma [stock_market_widget type=”chart” template=”line” assets=”RGT.AX” range=”1mo” interval=”1d” price_field=”close” border_width=”3″ tension=”0.5″ line_color=”#5679FF” range_selector=”true” axes=”true” cursor=”true” api=”yahoo-finance”] Argent BioPharma has managed to overcome the wider chaos on the stock markets this week, seeing its stock jump over 40% in the wake of two major announcements.
Ananda Pharma, now the leading force in pharmaceutical cannabis research in the UK, has announced that the former Chief Operating Officer of GW Pharmaceuticals and Jazz Pharmaceuticals will join its team.
Earlier this week, Jazz dismissed a patent claim against Apotex, Canada’s largest generic drug producer, as it reached a settlement with the company, the details of which were undisclosed.
A groundbreaking achievement is flying under the radar. Epidiolex, the first FDA approved cannabis-derived drug developed by GW Pharmaceuticals, is on track to surpass $1 billion in annual revenue—a feat that puts it in the league of blockbuster drugs like Humira and Lipitor.
British American Tobacco [stock_market_widget type=”chart” template=”line” assets=”BATS.L” range=”1mo” interval=”1d” price_field=”close” border_width=”3″ tension=”0.5″ line_color=”#5679FF” range_selector=”true” axes=”true” cursor=”true” api=”yahoo-finance”] Tobacco giant British American Tobacco (BAT) has announced the launch of a second investment fund as part of its corporate venture arm, Btomorrow Ventures (BTV).
Jazz Pharmaceuticals [stock_market_widget type=”chart” template=”line” assets=”JAZZ” range=”1mo” interval=”1d” price_field=”close” border_width=”3″ tension=”0.5″ line_color=”#5679FF” range_selector=”true” axes=”true” cursor=”true” api=”yahoo-finance”] The pharmaceutical giant announced last week that its flagship cannabinoid treatment, Epidyolex, failed to pass its Phase 3 clinical trial in Japan.
As reported by Cannabis Health Avata Biosciences is developing solid dose cannabinoid medicines for epilepsy and other neurological disorders, with a number of former GW Pharmaceutical bosses on board.
